CYTOR is known to be up-regulated in many different cancers, including gastric, lung adenocarcinoma, renal cell carcinoma, and other cancers, and its expression is significantly associated with poor survival as well as lymph node metastasis [42]. Here, CYTOR is linked to metastatic malignant neoplasm in the lymph nodes.